WVE News and Press, Wave Life Sciences Ltd. From 07/20/21

Wave Life Sciences (WVE) announces that multiple participants have initiated dosing in the Phase 1b/2a FOCUS-C9 clinical trial evaluating WVE-004 as an investigational treatment for C9orf72-associated amyotrophic lateral sclerosis (C9-ALS) and frontotemporal dementia (C9-FTD). The FOCUS-C9 tr...

First clinical dosing of a compound using PN backbone chemistry modifications Enrolling participants with C9-ALS, C9-FTD or mixed phenotype FOCUS-C9 is adaptive to enable rapid optimization of WVE-004 dosing Clinical data to enable decision-making on next steps f...

Wave Life Sciences (WVE) announces the first proof-of-concept in vivo data for RNA editing using endogenous ADAR enzymes in genetic disorder alpha-1 antitrypsin deficiency ((AATD)).ADAR editing resulted in therapeutically meaningful restoration of circulating functional AAT protein, the compa...

First proof-of-concept in vivo data for RNA editing using endogenous ADAR enzymes in alpha-1 antitrypsin deficiency ADAR editing resulted in therapeutically meaningful restoration of circulating functional AAT protein Wave’s program in alpha-1 antitrypsin deficien...

CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and C...

Wave Life Sciences (NASDAQ: WVE) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “This morning, WVE held its 1Q21 call. We also had the opportunity to catch up with management post the call. The most important takeaway from t...

Wave Life Sciences Ltd. (WVE) Q1 2021 Earnings Conference Call May 13, 2021 08:30 AM ET Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President & Chief Executive Officer Mike Panzara - Chief Medical Officer, Head of Therapeutics Discovery & Development Kyl...

The following slide deck was published by Wave Life Sciences Ltd. in conjunction with their 2021 Q1 earnings call. For further details see: Wave Life Sciences Ltd. 2021 Q1 - Results - Earnings Call Presentation

Clinical trials underway with next-generation candidates incorporating PN chemistry Clinical data from PN chemistry programs expected in 2022 In vivo ADAR editing data for AATD program on track for 1H 2021 Wave to host investor conference call and webcast at 8:30...

CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and C...